Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma.

Cancer medicine - 1 Jun 2026

Danno Tetsuya, Nakamura Seiji, Taguchi Satoru, Fujii Yoichi, Teshima Taro, Sato Yusuke, Kawai Taketo, Kobayashi Yukari, Nagaoka Koji, Ueda Yumi, Matoba Ryo, Kakimi Kazuhiro, Kume Haruki

Abstract excerpt

Advanced urothelial carcinoma (aUC) has a poor prognosis, and real-time monitoring of treatment response remains clinically challenging. Circulating tumor DNA (ctDNA) has emerged as a promising non-invasive biomarker that may reflect tumor burden and molecular response. In this study, we analyzed ctDNA dynamics using a urothelial carcinoma-specific mutation panel and the non-overlapping integrated read sequencing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Circulating Tumor DNA

Share to FGFR3 gene

Share to HRAS gene

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 42310468
DOI: 10.1002/cam4.72045
PMCID: PMC13275330

Genes

FGFR3
HRAS
KRAS
TERT
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma.PMID 42310468Read ↗

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.Semantic proximity Read ↗

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.Semantic proximity Read ↗

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.Semantic proximity Read ↗

Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.Semantic proximity Read ↗

Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.Semantic proximity Read ↗

Circulating Tumor DNA in Genitourinary Malignancies: Current Applications and Future PerspectivesSemantic proximity Read ↗

Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinomaSemantic proximity Read ↗

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Semantic proximity Read ↗

Molecular classification and diagnostics of upper urinary tract urothelial carcinoma.Semantic proximity Read ↗

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.Semantic proximity Read ↗

Novel Use of ctDNA to Identify Muscle-Invasive and Non-Organ Confined Upper Tract Urothelial CarcinomaSemantic proximity Read ↗

Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA : a 23‐gene panel with utility for non‐invasive diagnosis and risk stratificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.